Strides Pharma Science Limited Share Price Bombay S.E.

Equities

STAR

INE939A01011

Pharmaceuticals

Market Closed - Bombay S.E. 11:00:55 27/06/2024 BST 5-day change 1st Jan Change
940.7 INR -1.18% Intraday chart for Strides Pharma Science Limited -1.73% +45.08%

Financials

Sales 2024 40.51B 486M 38.39B Sales 2025 * 46.17B 553M 43.76B Capitalization 86.53B 1.04B 82.01B
Net income 2024 -706M -8.46M -669M Net income 2025 * 4.33B 51.87M 4.1B EV / Sales 2024 1.78 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.87 x
P/E ratio 2024
-101 x
P/E ratio 2025 *
19.7 x
Employees 2,850
Yield 2024 *
0.38%
Yield 2025 *
0.37%
Free-Float 65.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.18%
1 week-1.73%
Current month+9.12%
1 month+9.81%
3 months+21.75%
6 months+44.26%
Current year+45.08%
More quotes
1 week
927.15
Extreme 927.15
973.70
1 month
687.00
Extreme 687
994.30
Current year
644.50
Extreme 644.5
994.30
1 year
412.45
Extreme 412.45
994.30
3 years
263.45
Extreme 263.45
994.30
5 years
263.45
Extreme 263.45
1 000.00
10 years
263.45
Extreme 263.45
1 412.45
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/01/10
Founder 63 27/06/90
Compliance Officer - 02/02/17
Members of the board TitleAgeSince
Founder 63 27/06/90
Director/Board Member 80 17/05/17
Director/Board Member 64 26/07/12
More insiders
Date Price Change Volume
27/06/24 940.7 -1.18% 7 299
26/06/24 952 +0.76% 12,425
25/06/24 944.8 -0.14% 6,469
24/06/24 946.2 +0.21% 5,593
21/06/24 944.2 -0.22% 10,668

Delayed Quote Bombay S.E., June 27, 2024 at 11:00 am

More quotes
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
941.4 INR
Average target price
993.5 INR
Spread / Average Target
+5.53%
Consensus

Quarterly revenue - Rate of surprise